Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date

Peacock, Gina F; Sauvageot, Jurgita

Abstract

Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date

Author(s): Peacock Gina F, Sauvageot Jurgita

Issue: Sep/Oct 2012 - Volume 16, Number 5

View All Articles in Issue

Page(s): 428-430

Download in electronic PDF format for $75

Abstract

Transdermal acetaminophen in Pluronic lecithin organogel (APAP-PLO) has been anecdotally reported as beneficial when used in cancer patients in the hospice setting. However, there is currently no published information regarding the stability of APAP-PLO. The objective of this study was to identify an appropriate formulation of APAP-PLO and to evaluate the stability of that formulation in order to determine an appropriate beyond-use date. APAP-PLO 50% was prepared by a local compounding pharmacy and analyzed at 0, 7, 14, 28, 45, 60, 90, and 180 days using a stability-indicating high-performance liquid chromatographic method. The mean concentrations and standard deviations were determined for each time point. Physical stability was also assessed by visual observation at each time point. The beyond-use date was determined as the time period that the samples maintained at least 90 percent of the initial concentration. At 180 days, the APAP-PLO was physically stable as noted by visual observation, and the concentration was 102 ± 4.8 percent of initial concentration indicating that a beyond-use date of 180 days would be appropriate for this formulation.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Sep/Oct 2012 Pg. 428-430	Evaluation of the Stability of Acetaminophen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-Use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Mar/Apr 2003 Pg. 106-113	Veterinary Transdermal Medications: A to Z Author(s): Davidson Gigi S
May/Jun 2014 Pg. 253-255	Evaluation of the Stability of Fluoxetine in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2014 Pg. 345-347	Evaluation of the Stability of Promethazine Hydrochloride in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita
Jul/Aug 2014 Pg. 348-350	Evaluation of the Stability of Ketoprofen in Pluronic Lecithin Organogel and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita, Addo Richard T
Mar/Apr 2019 Pg. 146	Acetaminophen 50% Pluronic Lecithin Organogel Gel Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 256-261	Preparation and In Vitro Evaluation of a Pluronic Lecithin Organogel Containing Ricinoleic Acid for Transdermal Delivery Author(s): Boddu Sai HS, Bonam Sindhu Prabha, Wei Yangjie, Alexander Kenneth
Jan/Feb 2021 Pg. 73-81	Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design Author(s): Patel Gopesh, Davis Countaney, Liu Yi, Ip Kendice, Debideen Krystal E, Anderson Stephanie, Byrne Robert, Herr Dylan, Rhoads Melissa Merrell, Caputo Ross, Banov Daniel, Bassani August S
Nov/Dec 2010 Pg. 522-525	Stability of Methimazole in Poloxamer Lecithin Organogel to Determine Beyond-Use Date Author(s): Pignato Alyssa, Pankaskie Marvin, Birnie Christine
May/Jun 2013 Pg. 247-253	Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Jan/Feb 2016 Pg. 81-85	Evaluation of the Stability of Mercaptopurine Suspension Compounded in a Commercial Vehicle and the Determination of an Appropriate Beyond-use Date Author(s): Peacock Gina F, Sauvageot Jurgita, Hill Ashley, Killian Alyssa
Sep/Oct 2023 Pg. 424-430	Evaluation of Compounded Transdermal Analgesic Formulations Using the Franz Finite Dose Model Author(s): Baneshi Marzieh, Tyagi Deependra, Panneerselvam Ezilrani, MacKenzie Graham, Coleman Johngary, Zhang Shine X
Jan/Feb 2022 Pg. 65-71	Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2012 Pg. 62-63	The Use of Pluronic Lecithin Organogels in the Transdermal Delivery of Drugs Author(s): Bramwell Bethany L, Williams LaVonn A
Mar/Apr 2017 Pg. 164-170	Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
Nov/Dec 2014 Pg. 456-460	Standards of Practice, Professional Judgment, and Scientific Evidence to Establish and Extend a Beyond-Use Date Author(s): Thomson Cassandra Marie, Savji Taslim
Sep/Oct 2008 Pg. 447	Acetaminophen 10-mg/mL Rectal Solution Author(s): Allen Loyd V Jr
Jan/Feb 2021 Pg. 42	Acetaminophen (Paracetamol) 50 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
May/Jun 2023 Pg. 232-233	Acetaminophen 500-mg/mL Rectal Solution Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 180-183	The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP Author(s): Allen Loyd V Jr